38,166 Gilead Sciences, Inc. $GILD Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 298,739 shares of the biopharmaceutical company’s stock after selling 38,166 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Gilead Sciences were worth $44,527,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Gilead Sciences during the second quarter valued at approximately $15,393,785,000. State Street Corp raised its stake in Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after buying an additional 1,357,967 shares in the last quarter. Amundi lifted its holdings in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after buying an additional 1,018,976 shares during the period. Legal & General Group Plc purchased a new stake in Gilead Sciences during the second quarter worth $1,316,606,000. Finally, Deutsche Bank AG purchased a new stake in Gilead Sciences during the second quarter worth $918,387,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GILD. Barclays dropped their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Zacks Research cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Thursday, October 8th. Finally, Royal Bank Of Canada raised their price objective on Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a research report on Thursday, October 8th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $159.63.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00. Following the completion of the sale, the chief executive officer owned 566,683 shares of the company’s stock, valued at approximately $83,812,415.70. This trade represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock valued at $15,877,860 in the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $156.51 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51. The stock has a fifty day moving average price of $148.01 and a 200-day moving average price of $137.50. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market cap of $194.06 billion, a PE ratio of -58.62 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the firm earned $2.01 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were paid a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success strengthens the pipeline. Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data were described as “highly competitive,” supporting management’s strategy to expand into immunology and inflammatory bowel disease. Success in a large market could diversify Gilead beyond its HIV franchise. Gilead’s highly competitive mid-stage ulcerative colitis data validate I&I push
• Positive Sentiment: Bank of America raised its price target and maintained a Buy rating. The target increased from $168 to $172, implying roughly 10% upside from the referenced price and signaling confidence in Gilead’s earnings outlook and pipeline prospects.
• Positive Sentiment: Recent FDA decisions add commercial catalysts. Gilead received approval for the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval for Hepcludex in chronic hepatitis delta. The company will also present 28 HIV and antiviral research findings at IDWeek 2026, potentially providing additional clinical updates. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and quantitative sentiment improved. Gilead was upgraded to Zacks Rank #2 (Buy), reflecting improving expectations for earnings prospects. Separately, 43 ETFs added Gilead shares, indicating some institutional demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Investors are weighing acquisitions against Gilead’s dependable HIV cash flow. Biktarvy and other HIV products continue to support recurring revenue and the dividend, but acquisitions such as Arcellx and Tubulis have increased research and integration costs. Gilead reportedly recorded a substantial trailing loss as it absorbs those investments.
• Negative Sentiment: ETF selling and near-term profitability concerns could limit gains. ETFs were also reported as net sellers of Gilead on October 16, while coverage noted that the ulcerative-colitis trial win initially failed to lift the stock. Investors may remain focused on acquisition-related expenses and the path back to sustainable positive earnings. ETFs Are Net Sellers of Gilead Sciences

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.